A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board
Tóm tắt
Từ khóa
Tài liệu tham khảo
International Lymphoma Study Group, 1997, A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project, Blood, 89, 3909, 10.1182/blood.V89.11.3909
Anderson, 1998, Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project, Ann Oncol, 9, 717, 10.1023/A:1008265532487
Ganti, 2005, Follicular lymphoma: expanding therapeutic options, Oncology (Williston Park), 19, 213
Rueda, 2012, Has the time to come leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients?, BMC Cancer, 12, 210, 10.1186/1471-2407-12-210
Perry, 2013, Classification of non-Hodgkin lymphoma in six geographic regions around the world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project [abstract], Hematol Oncol, 31, 120
Canadian Cancer Society. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics. Canadian Cancer Society. Available at: http://www.cancer.ca/∼/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/canadian-cancer-statistics-2013-EN.pdf. Accessed March 18, 2014.
Canadian Cancer Society. Canadian Cancer Statistics. Available at: http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on. Accessed March 18, 2014.
Solal-Céligny, 1998, Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial, J Clin Oncol, 16, 2332, 10.1200/JCO.1998.16.7.2332
Jaffe, 2009, The 2008 WHO classification of lymphomas: implications for clinical practice and translational research, Hematology Am Soc Hematol Educ Program, 523, 10.1182/asheducation-2009.1.523
Solal-Céligny, 2004, Follicular lymphoma international prognostic index, Blood, 104, 1258, 10.1182/blood-2003-12-4434
Federico, 2009, Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project, J Clin Oncol, 27, 4555, 10.1200/JCO.2008.21.3991
Kenkre, 2012, What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma?, Cancer J, 18, 383, 10.1097/PPO.0b013e31826aed6d
Czuczman, 2006, Controversies in follicular lymphoma: “who, what, when, where, and why?” (not necessarily in that order!), Hematology Am Soc Hematol Educ Program, 303, 10.1182/asheducation-2006.1.303
Fisher, 2005, New treatment options have changed the survival of patients with follicular lymphoma, J Clin Oncol, 23, 8447, 10.1200/JCO.2005.03.1674
Zelenetz, 2013, Non-Hodgkin's lymphomas, version 1.2013, J Natl Compr Canc Netw, 11, 257, 10.6004/jnccn.2013.0037
Dreyling, 2011, ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 22, vi59, 10.1093/annonc/mdr388
McNamara, 2012, Guidelines on the investigation and management of follicular lymphoma, Br J Haematol, 156, 446, 10.1111/j.1365-2141.2011.08969.x
Zinzani, 2013, SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma, Am J Hematol, 88, 185, 10.1002/ajh.23372
López-Guillermo, 2011, Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma, Leuk Lymphoma, 52, 1, 10.3109/10428194.2011.629897
Alberta Health Services. Alberta Health Services. Lymphoma. Clinical Practice Guideline LYHE-002 (version 8). Available at: http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-lyhe002-lymphoma.pdf. Accessed August 9, 2014.
British Colombia Cancer Agency. Cancer management guidelines. Malignant lymphoma. British Colombia Cancer Agency, 2013. Available at: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Lymphoma/HD/default.htm. Accessed August 9, 2014.
Sabio R. Canadian guideline needed for the treatment of follicular lymphoma (Available at: http://www.newevidence.com/oncology/entries/Canadian_Guideline_Needed_for_the_Treatment/). Accessed: June 23, 2014.
National Comprehensive Cancer Network. NCCN categories of evidence and consensus. Available at: http://www.nccn.org/professionals/physician_gls/categories_of_consensus.asp. Accessed: March 18, 2014.
Pugh, 2010, Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis, Cancer, 116, 3843, 10.1002/cncr.25149
Michallet, 2013, Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?, J Hematol Oncol, 6, 45, 10.1186/1756-8722-6-45
Campbell, 2010, Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy, Cancer, 116, 3797, 10.1002/cncr.25117
Wilder, 2001, Long-term results with radiotherapy for stage I-II follicular lymphomas, Int J Radiat Oncol Biol Phys, 51, 1219, 10.1016/S0360-3016(01)01747-3
Frank, 2001, Centroblastic-centrocytic non-Hodgkin's lymphoma stage I-III: patterns of failure following radiotherapy, Strahlenther Onkol, 177, 597, 10.1007/PL00002370
Ha, 2003, Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study, Int J Radiat Oncol Biol Phys, 57, 316, 10.1016/S0360-3016(03)00592-3
Guadagnolo, 2006, Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy, Int J Radiat Oncol Biol Phys, 64, 928, 10.1016/j.ijrobp.2005.08.010
Guckenberger, 2012, Radiotherapy alone for stage I-III low grade follicular lymphoma: long-term outcome and comparison of extended field and total nodal irradiation, Radiat Oncol, 7, 103, 10.1186/1748-717X-7-103
Fakhrian, 2012, Radiotherapy in stage I-III follicular non-Hodgkin lymphoma. Retrospective analysis of a series of 50 patients, Strahlenther Onkol, 188, 464, 10.1007/s00066-011-0057-0
Ahmed, 2013, Early stage W.H.O. grade I and II follicular lymphoma treated with radiation therapy alone, PLoS One, 8, e65156, 10.1371/journal.pone.0065156
Friedberg, 2012, Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study, J Clin Oncol, 30, 3368, 10.1200/JCO.2011.40.6546
Lowry, 2011, Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial, Radiother Oncol, 100, 86, 10.1016/j.radonc.2011.05.013
Hoppe
Petersen, 2004, Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone [abstract], J Clin Oncol, 22, 6521, 10.1200/jco.2004.22.14_suppl.6521
Engelhard, 2011, Follicular lymphoma: curability by radiotherapy in limited stage nodal disease? Updated results of a randomized trial [abstract], Ann Oncol, 22, iv90
Seymour, 2003, Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma, J Clin Oncol, 21, 2115, 10.1200/JCO.2003.07.111
Advani, 2004, Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy, J Clin Oncol, 22, 1454, 10.1200/JCO.2004.10.086
Ardeshna, 2003, Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial, Lancet, 362, 516, 10.1016/S0140-6736(03)14110-4
Brice, 1997, Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte, J Clin Oncol, 15, 1110, 10.1200/JCO.1997.15.3.1110
Young, 1988, The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment, Semin Hematol, 25, 11
Kahl, 2011, Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized phase iii study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma [abstract], Blood, 118, LBA-6, 10.1182/blood.V118.21.LBA-6.bld0076_P3_LBA-6
Ardeshna, 2014, Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial, Lancet Oncol, 15, 424, 10.1016/S1470-2045(14)70027-0
McLaughlin, 1998, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program, J Clin Oncol, 16, 2825, 10.1200/JCO.1998.16.8.2825
Hainsworth, 2002, Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma, J Clin Oncol, 20, 4261, 10.1200/JCO.2002.08.674
Bachy, 2013, Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma, Haematologica, 98, 1107, 10.3324/haematol.2012.082412
Marcus, 2005, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, 105, 1417, 10.1182/blood-2004-08-3175
Marcus, 2008, Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma, J Clin Oncol, 26, 4579, 10.1200/JCO.2007.13.5376
Herold, 2007, Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study, J Clin Oncol, 25, 1986, 10.1200/JCO.2006.06.4618
Salles, 2008, Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study, Blood, 112, 4824, 10.1182/blood-2008-04-153189
Federico, 2013, R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi, J Clin Oncol, 31, 1506, 10.1200/JCO.2012.45.0866
Rummel, 2013, Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial, Lancet, 381, 1203, 10.1016/S0140-6736(12)61763-2
Flinn, 2014, Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study, Blood, 123, 2944, 10.1182/blood-2013-11-531327
Rummel, 2005, Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma, J Clin Oncol, 23, 3383, 10.1200/JCO.2005.08.100
Robinson, 2008, Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma, J Clin Oncol, 26, 4473, 10.1200/JCO.2008.17.0001
Kahl, 2010, Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study, Cancer, 116, 106, 10.1002/cncr.24714
Morschhauser, 2009, Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence, Oncologist, 14, 17, 10.1634/theoncologist.2009-S2-17
Salles, 2011, Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, Lancet, 377, 42, 10.1016/S0140-6736(10)62175-7
van Oers, 2010, Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study, J Clin Oncol, 28, 2853, 10.1200/JCO.2009.26.5827
Hochster, 2009, Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study, J Clin Oncol, 27, 1607, 10.1200/JCO.2008.17.1561
Morschhauser, 2013, 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial, J Clin Oncol, 31, 1977, 10.1200/JCO.2012.45.6400
Morschhauser, 2008, Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma, J Clin Oncol, 26, 5156, 10.1200/JCO.2008.17.2015